Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 10

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1
Chunk 10
---
 discovered by Toray. We are also working on proprietary Boltbody ISAC programs targeting CEA and PD-L1 and will be seeking partners for those programs.  

BDC-3042, our dectin-2 agonist antibody program, leverages our myeloid biology expertise to target tumor associated macrophages (TAMs). We have completed enrollment of our dose escalation study without any dose-limiting toxicities and will be reporting results from the Phase 1 study in the second quarter of 2025.

Our Pipeline 

We are leveraging our myeloid biology expertise to build a robust pipeline of immuno-oncology product candidates, including multiple Boltbody ISACs and a unique agonist antibody that targets tumor-associated macrophages. In addition to these programs, we are exploring various well-known targets that have been traditionally difficult to drug and where our myeloid expertise and the Boltbody ISAC approach may unlock the potential of these promising antigens as viable cancer targets. We currently hold exclusive worldwide rights to all of our proprietary development programs. 

3

Table of Contents

BDC-3042 is an agonist antibody targeting dectin-2, an innate immune receptor found on the surface of macrophages. dectin-2 is selectively expressed in TAMs across a broad range of tumor types, including non-small cell lung, head and neck, ovarian, triple-negative breast cancer, and melanoma, among others. Most of these TAMs seem to be immunosuppressive, and agonism of dectin-2 converts them to an immunostimulatory phenotype, inducing pro-inflammatory cytokine production, enhanced phagocytosis, and antigen processing and presentation. A dectin-2 agonist antibody has the potential to convert these immunosuppressive TAMs into tumor-destructive macrophages that elicit productive anti-tumor immune responses. Anti-PD-1 therapies have been shown to upregulate the expression of dectin-2 in tumors, which provides an interesting rationale for exploring this combination. In October 2023, we dosed the first patient with BDC-3042 in the Phase 1 dose-escalation study in patients with a broad range of solid tumors. We have completed enrollment of our dose escalation study without any dose-limiting toxicities and we expect to be reporting results from the Phase 1 study in the second quarter of 2025.

BDC-4182 utilizes our next-generation Boltbody™ ISAC technology platform and